Beta Drugs Ltd vs Ind Swift Laboratories Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 03, 2026

Key Highlights

The Latest Trading Price of Beta Drugs Ltd is ₹ 1330 as of 30 Apr 15:30 . The P/E Ratio of Beta Drugs Ltd changed from 9.8 on March 2021 to 45.3 on March 2025 . This represents a CAGR of 35.82% over 5 yearsThe P/E Ratio of Ind-Swift Laboratories Ltd changed from 6.9 on March 2023 to 2.3 on March 2025 . This represents a CAGR of -30.66% over 3 years The Market Cap of Beta Drugs Ltd changed from ₹ 115.37 crore on March 2021 to ₹ 1923 crore on March 2025 . This represents a CAGR of 75.55% over 5 yearsThe Market Cap of Ind-Swift Laboratories Ltd changed from ₹ 425.72 crore on March 2021 to ₹ 509.08 crore on March 2025 . This represents a CAGR of 3.64% over 5 years The revenue of Beta Drugs Ltd for the Dec '25 is ₹ 89.58 crore as compare to the Sep '25 revenue of ₹ 106.37 crore. This represent the decline of -15.78% The revenue of Ind-Swift Laboratories Ltd for the Dec '25 is ₹ 178.43 crore as compare to the Sep '25 revenue of ₹ 170.5 crore. This represent the growth of 4.65% The ebitda of Beta Drugs Ltd for the Dec '25 is ₹ 19.3 crore as compare to the Sep '25 ebitda of ₹ 24.3 crore. This represent the decline of -20.58% The ebitda of Ind-Swift Laboratories Ltd for the Dec '25 is ₹ 25.9 crore as compare to the Sep '25 ebitda of ₹ 19.34 crore. This represent the growth of 33.92% The net profit of Beta Drugs Ltd changed from ₹ 8.95 crore to ₹ 8.52 crore over 5 quarters. This represents a CAGR of -3.86% The net profit of Ind-Swift Laboratories Ltd changed from ₹ 1.01 crore to ₹ 9.52 crore over 7 quarters. This represents a CAGR of 260.37% The Dividend Payout of Beta Drugs Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Ind-Swift Laboratories Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Beta Drugs Ltd

Beta Drugs Limited was incorporated as a private limited company with the name 'Beta Drugs Private limited' at Himachal Pradesh on September 21, 2005.
Subsequently, the company was converted in to public limited company and the name of the company was changed to 'Beta Drugs Limited' on August 11, 2017 Beta Drugs is a part of Adley Group.
Adley Group was founded in the year 1985, by its promoter Vijay Batra, who has more than twenty five years of experience in manufacture of pharmaceutical products in India.
The Company is a pharmaceutical formulation manufacturing company engaged in developing, manufacturing and marketing of drug products for domestic and international customers.
The Promoter Vijay Batra, took over the company from Kiran Goyal, Deepak Kumar Prince Bharti and Rohit Bansal in the year 2014.

About Ind-Swift Laboratories Ltd

Ind-Swift Laboratories Limited is a part of the Ind-Swift Group and is based at Chandigarh, Punjab, India.
The Company is one of the leading manufacturers of APIs catering to global and domestic formulators.
Based in Chandigarh, India, the Company operated two advanced manufacturing facilities in Derabassi and Jammu, adhering to international standards.
Ind-Swift Laboratories Ltd. is recognised globally as a leader in the Macrolide Antibiotic sector, and its products are well-regarded by major pharmaceutical formulators worldwide. Ind-Swift Laboratories Limited was incorporated on January 4, 1995 as a joint venture between Ind-Swift Ltd and Punjab State Industrial Development Corporation.
Later, Ind-Swift purchased Punjab State Industrial Development Corporation equity to emerge as a single largest shareholder in the company.

FAQs for the comparison of Beta Drugs Ltd and Ind-Swift Laboratories Ltd

Which company has a larger market capitalization, Beta Drugs Ltd or Ind-Swift Laboratories Ltd?

Market cap of Beta Drugs Ltd is 1,348 Cr while Market cap of Ind-Swift Laboratories Ltd is 1,190 Cr

What are the key factors driving the stock performance of Beta Drugs Ltd and Ind-Swift Laboratories Ltd?

The stock performance of Beta Drugs Ltd and Ind-Swift Laboratories Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Beta Drugs Ltd and Ind-Swift Laboratories Ltd?

As of May 3, 2026, the Beta Drugs Ltd stock price is INR ₹1330.1. On the other hand, Ind-Swift Laboratories Ltd stock price is INR ₹137.15.

How do dividend payouts of Beta Drugs Ltd and Ind-Swift Laboratories Ltd compare?

To compare the dividend payouts of Beta Drugs Ltd and Ind-Swift Laboratories Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.